🇺🇸 kava (Piper methysticum) in United States
19 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 19
Most-reported reactions
- Abdominal Discomfort — 2 reports (10.53%)
- Abdominal Pain — 2 reports (10.53%)
- Decreased Appetite — 2 reports (10.53%)
- Diarrhoea — 2 reports (10.53%)
- Fatigue — 2 reports (10.53%)
- Intentional Dose Omission — 2 reports (10.53%)
- Nausea — 2 reports (10.53%)
- Product Dose Omission Issue — 2 reports (10.53%)
- Somnolence — 2 reports (10.53%)
- Abdominal Distension — 1 report (5.26%)
Other Psychiatry/Neurology approved in United States
Frequently asked questions
Is kava (Piper methysticum) approved in United States?
kava (Piper methysticum) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for kava (Piper methysticum) in United States?
National Institutes of Health Clinical Center (CC) is the originator. The local marketing authorisation holder may differ — check the official source linked above.